医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Korean Cosmetic Brand PETITCOMO Launches Bling Bling Light Up Masks for Summer Skin Treatment

2019年07月05日 PM01:44
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

PETITCOMO, a Korean cosmetic brand, has launched two types of Bling Bling Light Up Masks which contain EWG green grade natural ingredients.

These new sheet masks, Ampoule Mask Black Edition and Aqua Mask White Edition, infuse elasticity and vividness into skins affected by hot weather. They are also effective for improving skin tone.

Ampoule Mask Black Edition contains a variety of ingredients such as propolis extract, royal jelly extract, lavender oil, and orange peel oil which are great for skin nourishment and elasticity improvement. Meanwhile, Aqua Mask White Edition soothes heat-affected skins by infusing a rich and comfort watery feeling with its ingredients including Lactobacillus fermentum, purslane extract, and chamomile oil.

The masks’ triple-layer-embossing Bella soft sheets are made of bamboo which enables high adherence and low irritation to the skin.

“These mask products are made by the renowned cosmetic brand, featuring high-quality natural ingredients and advanced technology. Users will recognize its moisturizing effects immediately after using this product. The products also make their makeup more effective,” said an official from AMAX HOLDINGS, a manufacturer of PETITCOMO. “We are preparing to launch a variety of new lineup consistently.”

AMAX HOLDINGS has gained much attention with its stage-by-stage skincare program ACOLAB Miracle System Total Solution, which allows consumers to manage their skin themselves at home like an expert from a professional aesthetic shop at low cost.

ACOLAB Miracle System Total Solution is composed of several stages from peeling gel, MTS to soothing recovery cream care.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190704005356/en/

CONTACT

For AMAX HOLDINGS

ADExpo Korea Co., Ltd.

Jinju Lee, +82-2-6010-1102

adexpo@adexpo.co.kr

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表